Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 12.6% in January

Immunome, Inc. (NASDAQ:IMNM) saw a large drop in short interest in January. As of January 15th, there was short interest totaling 15,314,650 shares, a drop of 12.6% from the December 31st total of 17,532,234 shares. Based on an average daily trading volume, of 2,451,335 shares, the days-to-cover ratio is currently 6.2 days. Approximately 18.1% of the shares of the company are short sold. Approximately 18.1% of the shares of the company are short sold. Based on an average daily trading volume, of 2,451,335 shares, the days-to-cover ratio is currently 6.2 days.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Leerink Partners set a $40.00 price objective on shares of Immunome in a research report on Monday, December 15th. Truist Financial assumed coverage on Immunome in a report on Monday, December 1st. They set a “buy” rating and a $36.00 price target for the company. Guggenheim lifted their price objective on Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Lake Street Capital increased their target price on shares of Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Finally, Stephens upped their price target on shares of Immunome from $25.00 to $33.00 and gave the stock an “overweight” rating in a research report on Monday, November 17th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $31.00.

Insiders Place Their Bets

In related news, insider Philip Tsai acquired 10,000 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were bought at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the completion of the transaction, the insider directly owned 43,300 shares in the company, valued at approximately $887,217. This trade represents a 30.03% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the sale, the director directly owned 2,031,181 shares of the company’s stock, valued at approximately $44,157,874.94. This trade represents a 15.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders acquired 68,518 shares of company stock valued at $1,453,958. 7.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Stoneridge Investment Partners LLC lifted its position in shares of Immunome by 5.4% in the third quarter. Stoneridge Investment Partners LLC now owns 12,174 shares of the company’s stock worth $143,000 after buying an additional 620 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its stake in Immunome by 6.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 10,892 shares of the company’s stock worth $128,000 after acquiring an additional 631 shares during the last quarter. Creative Planning raised its holdings in shares of Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after acquiring an additional 710 shares in the last quarter. Teacher Retirement System of Texas boosted its position in shares of Immunome by 6.8% during the 2nd quarter. Teacher Retirement System of Texas now owns 18,548 shares of the company’s stock valued at $172,000 after acquiring an additional 1,188 shares during the last quarter. Finally, Main Management ETF Advisors LLC grew its holdings in shares of Immunome by 1.6% in the second quarter. Main Management ETF Advisors LLC now owns 76,944 shares of the company’s stock valued at $716,000 after purchasing an additional 1,248 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

IMNM stock opened at $26.14 on Tuesday. Immunome has a 1-year low of $5.15 and a 1-year high of $26.63. The business has a 50 day simple moving average of $21.45 and a two-hundred day simple moving average of $15.69. The company has a market capitalization of $2.40 billion, a price-to-earnings ratio of -8.86 and a beta of 2.22.

Immunome (NASDAQ:IMNM) last released its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. Sell-side analysts anticipate that Immunome will post -2.21 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.